3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
2
mCRPC
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer
1
Interventions
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Metastatic Hormone Sensitive Prostate Cancer
×
enzalutamide
×
Clear all
NCT02677896
2025-10-24
ARCHES
Astellas Pharma Inc
Phase 3
Completed
1,150 enrolled
23 charts
1 FDA